Roche, Eli Lilly and Taiho Pharmaceutical could this week learn whether the European Medicines Agency will recommend in favor of approving the EU marketing applications for their respective orphan drugs, glofitamab, pirtobrutinib and futibatinib.
Their products are among the drugs listed as being up for an opinion on the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?